Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

In patients with lower-risk myelodysplastic syndromes and red blood cell (RBC) transfusion–dependent anaemia and thrombocytopenia, oral azacitidine improved rate of RBC transfusion independence (31% v 11% placebo; P=0.0002), with median durations of 11.1 and 5.0 months.

Source:

Journal of Clinical Oncology